

Press Release - April 25, 2023

EG 427 announces participation to BIO €quity Europe, BIO International Convention, and Annual SCI Investor Symposium in May and June 2023

Paris, France, April 25, 2023 – EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions based on its unique non-replicative HSV-1 vector platform, announces today its participation to three major upcoming conferences.

- **BIO €quity Europe**, Dublin, Ireland, May 15-16, 2023
 - Dr. Philippe Chambon, Chief Executive Officer, will give an in-person presentation on Monday, May 15, at 3 pm IST in Liffey meeting room 2, about the company's latest results and corporate development.
 - Registration for the conference is open [here](#).
- **BIO International Convention**, Boston, MA, June 5-8, 2023
 - Dr. Philippe Chambon, Chief Executive Officer, and Mikael Contrastin, VP Strategy & BD, will attend within the French delegation.
- **Annual SCI Investor Symposium**, San Diego, CA, June 29, 2023
 - Dr. Cornelia Haag-Molkenteller, Chief Medical Officer, will give a presentation about the company's innovative approach on potential long-term solutions for patients living with Spinal Cord Injuries and other related chronic diseases
 - Join us to discuss the most recent advancements and future trends for treating spinal cord injuries with the whole community by registering [here](#).

To request a one-on-one meeting with our delegates, please contact info@eg427.com

About EG 427

EG 427 has developed a unique, non-replicative Herpes Simplex Virus type 1 (nrHSV-1) based vector platform. It delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes. We take advantage of it to design new treatments of peripheral nervous system disorders and beyond.


Our lead asset, EG110A, targets the silencing of type-C sensory neurons. It is first being developed in urology indications. Our earlier stage products are focused on modifying the neurotransmission of other subsets of neurons. Furthermore, we are building the necessary manufacturing efficiency to bring genomic medicine to more prevalent, high medical need indications.

Our HQ and labs are located in Paris, France.

For more information:

🌐 check our website at www.eg427.com

follows us on [LinkedIn](#) at www.linkedin.com/company/eg427/



EG 427

PINPOINT GENE THERAPY

Press Release - April 25, 2023

Contacts:

Company

Philippe Chambon, M.D., Ph.D.

EG 427 Founder and CEO

US: 415-533-9359

FR: +33 7 70 02 22 08

philippe@eg427.com

Media

US

Selina Husain / Robert Flamm, Ph.D.

Burns McClellan, Inc.

shusein@burnsmc.com

[mailto:/ rflamm@burnsmc.com](mailto:rflamm@burnsmc.com)

EU

Sophie Baumont

Rose Piquante Consulting

sophie.baumont@rosepiquante-consulting.com

